先天性血栓性血小板減少性紫斑病患者における組換えADAMTS13の調査

基本情報

NCT ID

NCT06441578

ステータス

募集中

試験のフェーズ

-

試験タイプ

観察

目標被験者数

40

治験依頼者名

Takeda

概要

This study is a survey in Japan of recombinant ADAMTS13 used to treat or to prevent participants with congenital thrombotic thrombocytopenic purpura (cTTP). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related from recombinant ADAMTS13 and to check if recombinant ADAMTS13 improves or prevents cTTP. During the study, participants with cTTP will take recombinant ADAMTS13 intravenous injection according to their clinic's standard practice. The study doctors will check for side effects from recombinant ADAMTS13 for 18 months.

対象疾患

介入

依頼者（Sponsor）